Core Viewpoint - A securities class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors by making overly positive statements while concealing material adverse facts [2][6]. Allegations - The lawsuit claims that C3.ai and its executives misled investors regarding the company's performance and potential [2]. - The CEO's health issues significantly hindered the company's ability to close deals, and management failed to minimize the impact of these health issues on operations [6]. Triggering Event - On August 8, 2025, C3.ai announced disappointing preliminary Q1 FY2026 results and cut full-year revenue guidance, attributing weak sales to "reorganization with new leadership" and the CEO's health problems [6]. Stock Impact - Following the announcement on August 8, 2025, C3.ai's stock closed at $22.13 per share and fell to $16.47 per share by August 11, 2025, representing a drop of approximately 25.6% in a single trading day [6]. Next Steps for Investors - Investors who suffered losses can seek appointment as lead plaintiff prior to October 21, 2025, by contacting Wolf Haldenstein [2][6].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to significant financial misrepresentations and integration issues related to its acquisition of 3M's food safety business, which led to substantial losses for investors during the specified class period [1][6]. Financial Performance - On January 10, 2025, Neogen reported a GAAP net income that was significantly negative, primarily due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, resulting in a share price decline from $13.07 to $12.36, approximately 5% [3]. - On April 9, 2025, Neogen's quarterly revenue fell by 3.4% to $221 million, leading to another cut in FY25 guidance and a share price drop from $7.04 to $5.02, approximately 28% [4]. - On June 4, 2025, Neogen disclosed a material decline in EBITDA margin attributed to elevated inventory write-offs, causing the share price to decline from $6.00 to $4.96, approximately 17% [5]. Lawsuit Details - The lawsuit alleges that Neogen misrepresented the status of the integration with 3M and failed to disclose the negative impacts of integration issues, misleading investors into believing that the integration was progressing smoothly [6].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against C3.ai, Inc. for alleged misrepresentations regarding the company's business and the impact of the CEO's health on its operations [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management failed to address the significant impact of the CEO's health on the company's ability to close deals and execute its profit and growth potential [2]. - Investors who purchased C3.ai securities between February 26, 2025, and August 8, 2025, are included in the class [1]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file papers by October 21, 2025, and representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4].

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Snap Inc. (“Snap” or the “Company”) (NYSE: SNAP) between April 29, 2025, and August 5, 2025, inclusive. For more information, submit a form at Snap Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030. A ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Flywire securities between February 28, 2024, and February 25, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 23, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that throughout the Class Period, Flywire's defendants made false and misleading statements regarding the sustainability of the company's revenue growth and the impact of permit and visa-related restrictions on its business [5]. - The lawsuit claims that these misleading statements resulted in investor damages when the true details about Flywire's business performance became public [5].

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [1][2]. Group 1: Company Performance - The IMPACT Phase 2b MASH trial results were released on June 26, 2025, revealing that while there was a positive trend in fibrosis improvement, the results did not meet statistical significance due to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [1]. Group 2: Legal Actions - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments in a class action lawsuit [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 6, 2025 [2]. Group 3: Firm's Commitment - The Gross Law Firm is dedicated to protecting the rights of investors affected by deceitful practices and aims to ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. following a significant drop in its stock price after the FDA rejected its drug application for RP1, intended for advanced melanoma treatment [1][2]. Group 1: Lawsuit Details - The lawsuit, Jboor v. Replimune Group, Inc., seeks to represent investors who acquired Replimune securities between November 22, 2024, and July 21, 2025 [1][4]. - The lead plaintiff deadline for the lawsuit is set for September 22, 2025 [4]. Group 2: FDA Rejection and Market Reaction - Replimune's stock price plummeted by 77% on July 22, 2025, following the FDA's rejection of its application for RP1, which was communicated through a "complete response letter" [2][9]. - The FDA indicated that the IGNYTE trial was not well-designed or controlled, leading to doubts about the drug's effectiveness [7][8]. Group 3: Allegations Against Replimune - The complaint alleges that Replimune made false and misleading statements regarding the IGNYTE study, overstating its prospects and failing to disclose the trial's inadequacies [6][5]. - The FDA's findings highlighted significant issues with the trial's patient population diversity, complicating the interpretation of results [8][7]. Group 4: Investigation and Whistleblower Information - Hagens Berman is investigating whether Replimune misled investors about the IGNYTE trial design and data [3][9]. - Whistleblowers with non-public information regarding Replimune are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [11].

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025, inclusive (the "Class Period"). The Complaint alleges that Defendants made false and/or misleading st ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and illegal kickbacks related to Medicare beneficiaries [4][6][7]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [6]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in stock price [7]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $75,000 between September 9, 2020, and May 1, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1][4]. - There is a deadline of October 10, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against SelectQuote [4]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [8].